<DOC>
	<DOC>NCT01192971</DOC>
	<brief_summary>This phase II trial will be studying how well Apatinib working in patients with liver cancer.</brief_summary>
	<brief_title>A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Histologically or cytologic confirmed advanced hepatocellular carcinoma Life expectancy of more than 3 months. ECOG performance scale 0 2. No cirrhosis with child pugh score A At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan. Adequate hepatic, renal, heart, and hematologic functions (platelets &gt; 90 × 109/L, neutrophil &gt; 1.5 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper limit of normal(ULN), and serum transaminase≤2.5×the ULN). signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure. Pregnant or breastfeeding women History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Any factors that influence the usage of oral administration Evidence of CNS metastasis Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure Receiving the therapy of thrombolysis or anticoagulation Abuse of alcohol or drugs Less than 4 weeks from the last clinical trial Disability of serious uncontrolled intercurrence infection. Treatment with potent CYP3A4 inhibitors and inducer with 7 and 12 days respectively, prior to study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hcc, apatinib, phase II, cancer</keyword>
</DOC>